Elixir Medical To Present Randomized Clinical Dataset Featuring World's First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023
Primary endpoint, six-month clinical and imaging data from clinical trial of DESyne BDS Plus stent system evaluating safety and efficacy of localized delivery of anticoagulants and an anti-proliferative agent designed to reduce the implant thrombotic risk
Source: dicardiology.com